Cassava Sciences | PTIE - Gross Profit On Sales


Cassava Sciences reported $-3.96M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
Abbott USD 6.54B 625M Dec/2025
Amgen USD 6.48B 307M Sep/2025
Biogen USD 1.65B 34.6M Dec/2025
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Cassava Sciences USD -3.96M 1.16M Sep/2025
Eisai JPY 168.85B 17.02B Dec/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Geron USD 46.71M 525K Dec/2025
J&J USD 16.6B 118M Dec/2025
Merck USD 13.42B 431M Sep/2025
Novartis USD 10.82B 695M Sep/2025
Novavax USD 23.89M 239.21M Sep/2024
Pfizer USD 3.54B 7.61B Sep/2025
Roche Holding CHF 22.09B 10.04B Dec/2025